STOCK TITAN

RTW funds exercise 1.25M Orchestra BioMed (NASDAQ: OBIO) pre-funded warrants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. reported that affiliated RTW funds exercised pre-funded warrants to acquire 1,250,032 shares of common stock at $0.0001 per share on a cashless basis. The issuer withheld 32 shares to satisfy the exercise price and issued 1,250,000 shares to the RTW funds.

After the transactions, the reporting parties indirectly held 9,556,095 shares of common stock and 2,386,331 pre-funded warrants. The RTW funds and their attribution parties are limited to beneficial ownership of no more than 19.99% of outstanding common stock following any exercise, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider RTW INVESTMENTS, LP, WONG RODERICK
Role null | null
Sold 32 shs ($132.16)
Type Security Shares Price Value
X Pre-Funded Warrants (Right to Buy) 1,250,032 $2.7499 $3.44M
X Common Stock 1,250,032 $0.0001 $125.00
Sale Common Stock 32 $4.13 $132.16
Holdings After Transaction: Pre-Funded Warrants (Right to Buy) — 2,386,331 shares (Indirect, See footnote); Common Stock — 9,556,095 shares (Indirect, See footnote)
Footnotes (1)
  1. On April 27, 2026, the RTW Funds exercised Pre-Funded Warrants to purchase an aggregate of 1,250,032 shares of the Issuer's common stock for $0.0001 a share. The RTW Funds exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding 32 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the RTW Funds of an aggregate of 1,250,000 shares. Held by certain affiliated funds (the "RTW Funds") managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein. The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the RTW Funds shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the RTW Funds, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
Shares exercised 1,250,032 shares Pre-funded warrants exercised on April 27, 2026
Exercise price $0.0001 per share Exercise price of pre-funded warrants
Shares issued 1,250,000 shares Net shares issued after 32 withheld to pay exercise price
Common stock holdings 9,556,095 shares Common shares indirectly held after transactions
Pre-funded warrants remaining 2,386,331 warrants Pre-funded warrants indirectly held after exercise
Beneficial ownership cap 19.99% of common stock Maximum beneficial ownership allowed after any exercise
Shares withheld 32 shares Shares withheld by issuer to satisfy exercise price
Warrant transaction price $2.7499 per warrant Price shown for derivative line tied to exercised warrants
Pre-Funded Warrants financial
"On April 27, 2026, the RTW Funds exercised Pre-Funded Warrants to purchase an aggregate of 1,250,032 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
cashless basis financial
"The RTW Funds exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding 32 of such shares"
An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.
beneficial ownership regulatory
"The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of their pecuniary interest therein"
Attribution Parties regulatory
"together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 19.99%"
Section 16 regulatory
"for purposes of Section 16 under the Securities Exchange Act of 1934, as amended"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RTW INVESTMENTS, LP

(Last)(First)(Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/27/2026X(1)1,250,032A$0.00019,556,095ISee footnote(2)
Common Stock04/27/2026S(1)32D$4.139,556,063ISee footnote(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Pre-Funded Warrants (Right to Buy)$0.000104/27/2026X(1)1,250,032 (3) (3)Common Stock1,250,032$2.74992,386,331ISee footnote(2)
1. Name and Address of Reporting Person*
RTW INVESTMENTS, LP

(Last)(First)(Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
WONG RODERICK

(Last)(First)(Middle)
40 10TH AVENUE, FLOOR 7

(Street)
NEW YORK NEW YORK 10014

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. On April 27, 2026, the RTW Funds exercised Pre-Funded Warrants to purchase an aggregate of 1,250,032 shares of the Issuer's common stock for $0.0001 a share. The RTW Funds exercised the Pre-Funded Warrants on a cashless basis, resulting in the Issuer's withholding 32 of such shares to satisfy the exercise price of the Pre-Funded Warrants, and the issuance to the RTW Funds of an aggregate of 1,250,000 shares.
2. Held by certain affiliated funds (the "RTW Funds") managed by RTW Investments, LP ("RTW"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein.
3. The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the RTW Funds shall not be entitled to exercise the Pre-Funded Warrants to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the RTW Funds, together with their Attribution Parties (as defined in the Pre-Funded Warrants), to exceed 19.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
/s/ Roderick Wong, for RTW Investments, LP, By: Roderick Wong, M.D., Managing Partner04/29/2026
/s/ Roderick Wong, By: Roderick Wong, M.D.04/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did RTW Investments report in this Form 4 for Orchestra BioMed (OBIO)?

RTW-affiliated funds exercised pre-funded warrants to acquire 1,250,032 Orchestra BioMed common shares at $0.0001 per share on a cashless basis. The issuer withheld 32 shares for the exercise price and issued 1,250,000 shares to the RTW funds.

How many Orchestra BioMed (OBIO) shares do the RTW funds hold after these transactions?

Following the reported transactions, the RTW funds indirectly hold 9,556,095 shares of Orchestra BioMed common stock. This total reflects the warrant exercise and the 32 shares withheld to cover the exercise price under the cashless exercise structure described.

What are the terms of the pre-funded warrants held in Orchestra BioMed (OBIO)?

The pre-funded warrants have no expiration date and are exercisable immediately at an exercise price of $0.0001 per share. However, exercises are limited so the RTW funds and their attribution parties do not exceed 19.99% beneficial ownership of Orchestra BioMed’s outstanding common stock.

How many Orchestra BioMed (OBIO) pre-funded warrants remain after the exercise?

After exercising 1,250,032 pre-funded warrants, the RTW funds still hold 2,386,331 pre-funded warrants. These remaining warrants are exercisable immediately, subject to the 19.99% beneficial ownership cap specified in the warrant terms and referenced in the Form 4 footnotes.

Did RTW or Roderick Wong fully claim beneficial ownership of these Orchestra BioMed (OBIO) securities?

The filing states the securities are held by affiliated RTW funds managed by RTW Investments, LP. RTW and Roderick Wong disclaim beneficial ownership of the reported securities for Section 16 purposes, except to the extent of their pecuniary interest in those positions.

Was there any actual open-market sale of Orchestra BioMed (OBIO) shares in this Form 4?

The Form 4 shows 32 shares coded as a sale, but the footnote explains they were withheld by the issuer to satisfy the exercise price in a cashless warrant exercise. This represents payment of the exercise cost rather than a discretionary open-market sale.